470 related articles for article (PubMed ID: 28422735)
21. Stem cell markers in glioma progression and recurrence.
Hattermann K; Flüh C; Engel D; Mehdorn HM; Synowitz M; Mentlein R; Held-Feindt J
Int J Oncol; 2016 Nov; 49(5):1899-1910. PubMed ID: 27600094
[TBL] [Abstract][Full Text] [Related]
22. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
[TBL] [Abstract][Full Text] [Related]
23. The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
Thistle JE; Hellberg Y; Mortensen K; Hamilton-Dutoit S; Kjærsgaard A; Cronin-Fenton D; Sørensen HT; Lash TL
Breast Cancer Res Treat; 2017 Oct; 165(3):633-643. PubMed ID: 28643021
[TBL] [Abstract][Full Text] [Related]
24. Crosstalks between Raf-kinase inhibitor protein and cancer stem cell transcription factors (Oct4, KLF4, Sox2, Nanog).
Lee S; Wottrich S; Bonavida B
Tumour Biol; 2017 Apr; 39(4):1010428317692253. PubMed ID: 28378634
[TBL] [Abstract][Full Text] [Related]
25. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
26. Prognostic evaluation of Nanog, Oct4, Sox2, PCNA, Ki67 and E-cadherin expression in gastric cancer.
Li N; Deng W; Ma J; Wei B; Guo K; Shen W; Zhang Y; Luo S
Med Oncol; 2015 Jan; 32(1):433. PubMed ID: 25491144
[TBL] [Abstract][Full Text] [Related]
27. Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer.
Sun L; Burnett J; Gasparyan M; Xu F; Jiang H; Lin CC; Myers I; Korkaya H; Liu Y; Connarn J; He H; Zhang N; Wicha MS; Sun D
Oncotarget; 2016 Aug; 7(32):51408-51422. PubMed ID: 27285982
[TBL] [Abstract][Full Text] [Related]
28. PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
Karicheva O; Rodriguez-Vargas JM; Wadier N; Martin-Hernandez K; Vauchelles R; Magroun N; Tissier A; Schreiber V; Dantzer F
Oncotarget; 2016 Sep; 7(39):64109-64123. PubMed ID: 27579892
[TBL] [Abstract][Full Text] [Related]
29. Heterodimer formation by Oct4 and Smad3 differentially regulates epithelial-to-mesenchymal transition-associated factors in breast cancer progression.
Mandal G; Biswas S; Roy Chowdhury S; Chatterjee A; Purohit S; Khamaru P; Chakraborty S; Mandal PK; Gupta A; de la Mare JA; Edkins AL; Bhattacharyya A
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2053-2066. PubMed ID: 29526821
[TBL] [Abstract][Full Text] [Related]
30. A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1.
Ming J; Ruan S; Wang M; Ye D; Fan N; Meng Q; Tian B; Huang T
Oncotarget; 2015 Dec; 6(38):40692-703. PubMed ID: 26517687
[TBL] [Abstract][Full Text] [Related]
31. LGR5 Is a Gastric Cancer Stem Cell Marker Associated with Stemness and the EMT Signature Genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1.
Wang B; Chen Q; Cao Y; Ma X; Yin C; Jia Y; Zang A; Fan W
PLoS One; 2016; 11(12):e0168904. PubMed ID: 28033430
[TBL] [Abstract][Full Text] [Related]
32. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of NANOG and KLF4 for breast cancer.
Nagata T; Shimada Y; Sekine S; Hori R; Matsui K; Okumura T; Sawada S; Fukuoka J; Tsukada K
Breast Cancer; 2014 Jan; 21(1):96-101. PubMed ID: 22528804
[TBL] [Abstract][Full Text] [Related]
34. Increased Expression of Gankyrin and Stemness Factor Oct-4 are Associated with Unfavorable Clinical Outcomes and Poor Benefit of Tamoxifen in Breast Carcinoma Patients.
Jahangiri R; Mosaffa F; EmamiRazavi A; Gharib M; Jamialahmadi K
Pathol Oncol Res; 2020 Jul; 26(3):1921-1934. PubMed ID: 31853860
[TBL] [Abstract][Full Text] [Related]
35. Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance.
Bekele RT; Venkatraman G; Liu RZ; Tang X; Mi S; Benesch MG; Mackey JR; Godbout R; Curtis JM; McMullen TP; Brindley DN
Sci Rep; 2016 Feb; 6():21164. PubMed ID: 26883574
[TBL] [Abstract][Full Text] [Related]
36. Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer.
Ryu HS; Park DJ; Kim HH; Kim WH; Lee HS
Hum Pathol; 2012 Apr; 43(4):520-8. PubMed ID: 22018628
[TBL] [Abstract][Full Text] [Related]
37. Embryonic stem cells markers Oct4 and Nanog correlate with perineural invasion in human salivary gland mucoepidermoid carcinoma.
Destro Rodrigues MF; Sedassari BT; Esteves CM; de Andrade NP; Altemani A; de Sousa SC; Nunes FD
J Oral Pathol Med; 2017 Feb; 46(2):112-120. PubMed ID: 27131799
[TBL] [Abstract][Full Text] [Related]
38. Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma.
Lengerke C; Fehm T; Kurth R; Neubauer H; Scheble V; Müller F; Schneider F; Petersen K; Wallwiener D; Kanz L; Fend F; Perner S; Bareiss PM; Staebler A
BMC Cancer; 2011 Jan; 11():42. PubMed ID: 21276239
[TBL] [Abstract][Full Text] [Related]
39. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
40. Association of OCT4, SOX2, and NANOG expression with oral squamous cell carcinoma progression.
Fu TY; Hsieh IC; Cheng JT; Tsai MH; Hou YY; Lee JH; Liou HH; Huang SF; Chen HC; Yen LM; Tseng HH; Ger LP
J Oral Pathol Med; 2016 Feb; 45(2):89-95. PubMed ID: 26211876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
